Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE
ChemedCHE
85.8-25.1%
HTF
Heartflow, Inc. Common StockHTFL
15.9+124%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.72-35.7%
Belden logo
BeldenBDC
$39.44+80.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$1.08+4.9%
Boston Beer logo
Boston BeerSAM
$343.91-10.0%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?
Bicara Therapeutics (BCAX) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of $13.15 in Q1 2026.
What does share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value mean?
This metric represents the average fair value of stock options granted to employees and directors as of the date of the grant, calculated using an option pricing model. It serves as the basis for recognizing stock-based compensation expense over the vesting period. Investors use this to gauge the cost of equity-based incentives and potential future dilution.